PAR-23-059: National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 26, 2026.
From the official notice on Grants.gov, last changed February 12, 2026. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeP01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$432,130
- Typical project length5 years
- P01, Research Program Project Grant. Several related research projects around one theme, with shared core facilities. Other open P01 notices.
Projects funded under PAR-23-059 were run by National Cancer Institute (NCI, 50 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-059 in the NIH Guide.
Key dates
| Posted | December 14, 2022 |
|---|---|
| Deadline | May 26, 2026 |
| Archived by Grants.gov | June 25, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
Funded under PAR-23-059 so far
NIH funded 50 projects under PAR-23-059 in fiscal 2024 to 2026, at 36 institutions. The median yearly award was $432,130.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Convergent Epigenetic Control of Neuroendocrine Cancers | Dana-Farber Cancer Inst | 2026 | $2.5 million |
| Mediators of Lung Adenocarcinoma Metastasis | Sloan-Kettering Inst Can Research | 2026 | $348,983 |
| RB1 Controlled Mechanisms Driving Neuroendocrine Prostate Cancer | Thomas Jefferson University | 2026 | $489,316 |
| Core A: Administrative Core | Univ of North Carolina Chapel Hill | 2026 | $314,391 |
| Tipping Points in Cancer | University of California-Irvine | 2026 | $2.1 million |
| Advancing Hormone Therapy for Endometrial Cancer | University of New Mexico Health Scis Ctr | 2026 | $2.5 million |
| Administrative Core | University of TX MD Anderson Can Ctr | 2026 | $218,549 |
| Core C - Computational and Quantitative Imaging Core | University of TX MD Anderson Can Ctr | 2026 | $379,762 |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-059 still open?
No. It closed on May 26, 2026.
Who can apply for National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)?
Closed May 26, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-23-059?
NIH RePORTER lists 50 projects funded under PAR-23-059 in fiscal 2024 to 2026, at 36 institutions. The most were at University of TX MD Anderson Can Ctr, Dana-Farber Cancer Inst, New York University School of Medicine.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
- NIH Research Program Projects (Parent P01 Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)